Compare AAL & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAL | IBRX |
|---|---|---|
| Founded | 1930 | 2014 |
| Country | United States | United States |
| Employees | 133700 | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 8.2B |
| IPO Year | 2004 | 2015 |
| Metric | AAL | IBRX |
|---|---|---|
| Price | $12.99 | $6.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 4 |
| Target Price | ★ $15.40 | $14.25 |
| AVG Volume (30 Days) | ★ 57.6M | 12.0M |
| Earning Date | 10-22-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $54,633,000,000.00 | $113,288,000.00 |
| Revenue This Year | $17.05 | $99.98 |
| Revenue Next Year | $6.71 | $108.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 0.78 | ★ 668.31 |
| 52 Week Low | $10.09 | $1.95 |
| 52 Week High | $18.79 | $12.43 |
| Indicator | AAL | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.54 | 40.20 |
| Support Level | $11.59 | N/A |
| Resistance Level | $13.16 | $8.62 |
| Average True Range (ATR) | 0.50 | 0.57 |
| MACD | -0.02 | -0.16 |
| Stochastic Oscillator | 34.13 | 27.59 |
American Airlines is the world's largest airline by aircraft, capacity, and scheduled revenue passenger miles. Its major US hubs are Dallas/Fort Worth, Charlotte, Chicago, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. It generates over 30% of US airline revenue connecting Latin America with destinations in the United States. After completing a major fleet renewal, the company has the youngest average fleet of US legacy carriers.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.